CSGS:NASDAQCSG Systems International, Inc. Analysis
Data as of 2026-03-27 - not real-time
$80.10
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
CSG Systems International is trading at $80.1, comfortably above its 20‑day and 50‑day SMAs (≈$79.9) and below the 200‑day SMA ($71.6), indicating a short‑term bullish bias within a longer‑term uptrend. Technical signals such as a bullish MACD crossover (0.12 vs 0.11) and a moderate RSI of 56 support continued price strength, while volume is increasing and the fear‑greed index reads "Greed" at 72. Fundamentally, the stock appears undervalued against its discounted cash‑flow estimate of $96.0, offering roughly 20% upside, and the forward PE of 14.6 suggests earnings acceleration. The dividend yield of 1.7% with a 64.6% payout ratio is backed by solid free cash flow, and recent hedge‑fund buying and a pending sale to NEC provide a positive catalyst. However, a high debt‑to‑equity ratio of over 200% and a PE well above the industry average temper enthusiasm.
Overall, the blend of bullish technicals, attractive valuation relative to DCF, and sustainable dividend makes CSG a compelling near‑term play, while the leverage and modest revenue growth warrant caution for longer horizons.
Overall, the blend of bullish technicals, attractive valuation relative to DCF, and sustainable dividend makes CSG a compelling near‑term play, while the leverage and modest revenue growth warrant caution for longer horizons.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish technical indicators (price above SMA20/50, bullish MACD, increasing volume)
- Support level near $79.5 and positive market sentiment (Greed index)
- Recent hedge‑fund accumulation and dividend continuation
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF‑based undervaluation providing ~20% upside
- Forward earnings growth implied by forward PE of 14.6
- Sustainable dividend supported by strong free cash flow
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High leverage (debt‑to‑equity >200%) could constrain future flexibility
- Modest revenue growth (2%) and competitive SaaS market dynamics
- Valuation approaching fair value as price aligns with DCF estimates
Key Metrics & Analysis
Financial Health
Revenue Growth2.00%
Profit Margin4.57%
P/E Ratio40.5
ROE19.74%
ROA6.66%
Debt/Equity203.33
P/B Ratio7.8
Op. Cash Flow$155.9M
Free Cash Flow$213.5M
Industry P/E32.6
Technical Analysis
TrendBullish
RSI56.1
Support$79.50
Resistance$80.48
MA 20$79.92
MA 50$79.80
MA 200$71.57
MACDBullish
VolumeIncreasing
Fear & Greed Index72.04
Valuation
Fair Value$96.04
Target Price$80.70
Upside/Downside0.75%
GradeUndervalued
TypeBlend
Dividend Yield1.70%
Risk Assessment
Beta0.56
Volatility3.71%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.